By targeting HER2 through different molecular mechanisms, EGFR inhibitors, and particularly HER2 inhibitors (including trastuzumab and the dual EGFR/HER2 inhibitor lapatinib), inhibit tumor growth, and induce apoptosis. Here, EGFR is linked to neoplasm.